EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH

View source ↗

Summary

The European Medicines Agency has authorized Leqembi (lecanemab) by Eisai GmbH for the treatment of Alzheimer's disease, addressing cognitive dysfunction associ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

Status: Authorised. Therapeutic area: Cognitive Dysfunction;Alzheimer Disease. MAH: Eisai GmbH. Decision date: 30/09/2025